Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/27/2015 07/28/2015 07/29/2015 07/30/2015 07/31/2015 Date
128.82(c) 129.76(c) 130.09(c) 125.46(c) 127.43(c) Last
753 587 475 192 458 279 580 877 412 927 Volume
-0.62% +0.73% +0.25% -3.56% +1.57% Change
More quotes
Financials ($)
Sales 2015 56,8 M
EBIT 2015 -439 M
Net income 2015 -244 M
Finance 2015 635 M
Yield 2015 -
Sales 2016 56,3 M
EBIT 2016 -525 M
Net income 2016 -286 M
Finance 2016 431 M
Yield 2016 -
PER 2015 -
PER 2016
EV / Sales 2015 178x
EV / Sales 2016 183x
Capitalization 10 740 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which discovery, development and commercialization of RNAi therapeutics.It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.The... 
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
07/31 ALNYLAM PHARMACEUTICALS : Introduces Phase 1/2 Clinical Trial for ALN-AAT
07/30 ALNYLAM PHARMACEUTICALS : to Webcast Conference Call Discussing Second Quarter 2..
07/30 ALNYLAM PHARMACEUTICALS : Launches Phase 1/2 Clinical Trial for ALN-AAT
07/29 ALNYLAM PHARMACEUTICALS : Initiates Phase 3 Open Label Extension Study "APOLLO-O..
07/27 ALNYLAM PHARMACEUTICALS : Initiates Phase 1/2 Clinical Trial for ALN-AAT, an Inv..
07/27 ALNYLAM PHARMACEUTICALS : Commences Phase 3 Open Label Extension Study (APOLLO-O..
07/24 ALNYLAM PHARMACEUTICALS : Commences Phase 3 Open Label Extension Study (APOLLO-O..
07/22 ALNYLAM PHARMACEUTICALS : to Reschedule First RNAi Roundtable Webcast
More news
Sector news : Biotechnology & Medical Research - NEC
07/31 QUINTILES TRANSNATIONAL : Announces Pricing of Secondary Public Offering
07/30 SEATTLE GENETICS : reports 2Q loss
07/30 QUINTILES TRANSNATIONAL : Announces Launch of Secondary Public Offering of Commo..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
07/27 Alnylam initiates Phase 1/2 ALN-AAT trial in liver disease
07/21 An Assessment Of Celgene's Deal For Receptos
07/20 Alnylam initiates open label extension study of patisiran in ATTR amyloidosis
07/06 Benitec And Bluebird Bio, Gene Therapy Coming Of Age?
06/25 Bluebird Feathers Nest While Going Is Good


Comments 
Advertisement
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEU...
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions